Evidence map›Paper›PMID 42186656›Full record

ArticleCureus2026

Hemoglobin Response to a Low-Iron Dose in Infantile Anemia.

Masahiko Kimura, Takeshi Taketani

Abstract read
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Masahiko KimuraPediatrics, Kimura Children and Family Clinic, Izumo, JPN.
Takeshi TaketaniPediatrics, Shimane University Faculty of Medicine, Izumo, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIron-deficiency anemia (IDA) is common during infancy, especially among infants exclusively breastfed after six months of age. The recommended therapeutic iron dose is 3-6 mg/kg/day; however, excessive iron load can be harmful due to alteration of the gut microbiome and oxidative stress to the developing organs. Lower doses of iron have shown efficacy in treating IDA in adults. This retrospective study evaluated the hemoglobin (Hb) response to a lower iron dose in infantile anemia.

methodsDuring health checkups for 9- to 10-month-old infants, anemia screening was conducted for those who were exclusively breastfed. Clinical parameters, including birth date, gestational age, birth weight, and body weight at the start of iron supplementation, were recorded. Venous blood samples were collected for a complete blood count (CBC). Infants with either Hb levels below 11.0 g/dL or mean corpuscular volume below 70 fL received a therapeutic iron trial. From March 2016 to November 2018, a fixed dose of elemental iron (soluble ferric pyrophosphate) 15 mg/day was administered (reference group), and from November 2018 to December 2023, a dose of 1 mg/kg/day was given (low-dose group). CBC measurements were repeated after four weeks, and Hb responses were compared between the two regimens.

resultsA total of 26 children in the reference group and 27 in the low-dose group were finally analyzed. The fixed 15 mg/day dose in the reference group corresponded to 1.8 (1.6-1.9) (median (interquartile range) mg/kg/day). Baseline clinical variables showed no statistically significant differences between the two groups. The median Hb increase was 1.6 g/dL and 1.5 g/dL, with 69% (18/26) and 70% (19/27) of children achieving an Hb level ≥ 1 g/dL, in the reference and low-dose groups, respectively. All 15 children (15/27, 56%) in the low-dose group, who met the new WHO anemia definition at the age of 6-23 months of Hb < 10.5 g/dL, had an Hb response ≥ 1.0 g/dL, with a median Hb response of 2.2 g/dL.

conclusionAn iron dose of 1 mg/kg/day was as effective as 15 mg/day (median: 1.8 mg/kg/day) in the Hb response. In all children with Hb < 10.5 g/dL, the iron dose of 1 mg/kg/day showed substantial Hb responses. These findings suggest that therapeutic iron doses lower than conventional recommendations may be effective for managing IDA and mitigating the harmful effects.

Indexed as

gut microbiomehemoglobin responseinfantiron-deficiency anemiaoxidative stresstherapeutic iron dosetherapeutic iron trial

Identifiers

PMID42186656
PMCPMC13198841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.